Our recognition
Latest stories
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results
- Hikma launches authorised generic of Nucynta® ER (tapentadol) extended-release in the US Press Release, Product 11 March 2026 Hikma launches authorised generic of Nucynta® ER (tapentadol) extended-release in the US
- Hikma R&D. Innovation in formulation development. Meet Hamza Qassim Story, Life at Hikma 11 March 2026 Hikma R&D. Innovation in formulation development. Meet Hamza Qassim
- Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes Press Release, Financial Results 26 February 2026 Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
- Hikma launches authorised generic of Nucynta® (tapentadol) in the US Press Release, Product 25 February 2026 Hikma launches authorised generic of Nucynta® (tapentadol) in the US
Related content